Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A malignant mixed epithelial neoplasm that arises from the ovary and is composed predominantly of serous and endocervical-type mucinous epithelium.
Biomarker and diagnostic research for ovarian seromucinous carcinoma has been reported in the published literature.
10 clinical trials registered. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 3 PHASE3, 5 PHASE2, 2 PHASE1. Research is primarily sponsored by academic and government institutions.
62 publications have been identified in PubMed for ovarian seromucinous carcinoma. Research spans Case Report / Case Series (37%), Basic Science / Preclinical (21%), and Review / Meta-Analysis (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 23 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 11:13 AM UTC
37%
Laboratory research | 13 | 21% |
Research summaries | 8 | 13% |
Testing and diagnosis research | 7 | 11% |
Disease patterns and progression | 7 | 11% |
Clinical study results | 4 | 6% |
Xu X (2026). [PMID: 41765653](https://pubmed.ncbi.nlm.nih.gov/41765653/). *Zhonghua Fu Chan Ke Za Zhi*. [Basic Science / Preclinical]
Li CL (2026). [PMID: 41957787](https://pubmed.ncbi.nlm.nih.gov/41957787/). *J Ovarian Res*. [Review / Meta-Analysis]
Liu JB (2026). [PMID: 42000384](https://pubmed.ncbi.nlm.nih.gov/42000384/). *Gynecol Oncol*. [Clinical Trial Publication]
Anschütz S (2026). [PMID: 41876551](https://pubmed.ncbi.nlm.nih.gov/41876551/). *Nat Commun*. [Basic Science / Preclinical]
Mezzapesa F (2026). [PMID: 40685312](https://pubmed.ncbi.nlm.nih.gov/40685312/). *Int J Gynecol Cancer*. [Epidemiology / Natural History]
Tashiro A (2026). [PMID: 41943778](https://pubmed.ncbi.nlm.nih.gov/41943778/). *Cureus*. [Basic Science / Preclinical]
Ordoñez Arrillaga A (2026). [PMID: 41579581](https://pubmed.ncbi.nlm.nih.gov/41579581/). *Rev Esp Patol*. [Review / Meta-Analysis]
Ali BM (2026). [PMID: 41988441](https://pubmed.ncbi.nlm.nih.gov/41988441/). *Oxf Med Case Reports*. [Case Report / Case Series]
Chang TY (2026). [PMID: 41411622](https://pubmed.ncbi.nlm.nih.gov/41411622/). *Cancer Res*. [Basic Science / Preclinical]
Ren Y (2026). [PMID: 41474616](https://pubmed.ncbi.nlm.nih.gov/41474616/). *Cancer Med*. [Epidemiology / Natural History]